An Observational Study of Epoetin Beta [Neorecormon] to Evaluate the Quality of Life in Patients on Dialysis With Chronic Renal Anemia

Roche

Status: Completed

Conditions: Anemia

Treatments: Drug: epoetin beta [NeoRecormon]

Study type: Observational

Funder types: Industry

Identifiers

NCT01105494

ML21906

Details and patient eligibility

About

This multicenter, prospective, observational study will evaluate the quality of life and the factors that influence the quality of life of epoetin beta [Neorecormon] in patients with renal chronic anemia, who are on dialysis. For each eligible patient data will be collected for 6 months. Target sample size is 5000-7000 patients.

Enrollment: 6,000 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients >/=18 years of age
• Dialysis patients with chronic renal anemia
• Written informed consent

Exclusion criteria

• Red blood cell transfusion in the previous 2 months
• Severe neuropsychological disorder
• Diabetic patients with serious complications

This trial is being conducted in Morocco.